Lynparza receives Health Canada approval as adjuvant treatment for patients with germline BRCA-mutated HER2-negative high-risk early breast cancer - read this article along with other careers information, tips and advice on BioSpace
A nationwide survey of breast oncology physicians shows a disconnect between their self-reported practices and the real-world findings on referral rates for genetic testing.
Health Canada approves Perjeta for use pre-surgery in patients with aggressive early breast cancer[1] newswire.ca - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newswire.ca Daily Mail and Mail on Sunday newspapers.